HIV-specific CD4 T cell responses to different viral proteins have discordant associations with viral load and clinical outcome
S Ranasinghe, M Flanders, S Cutler… - Journal of …, 2012 - Am Soc Microbiol
ABSTRACT A successful prophylactic vaccine is characterized by long-lived immunity,
which is critically dependent on CD4 T cell-mediated helper signals. Indeed, most licensed …
which is critically dependent on CD4 T cell-mediated helper signals. Indeed, most licensed …
HIV-infected macrophages as efficient stimulator cells for detection of cytotoxic T cell responses to HIV in seronegative and seropositive vaccine recipients
MJ McELRATH, M HOFFMAN… - AIDS research and …, 1994 - liebertpub.com
The induction of CD8+ CTL responses is a goal of most HIV-1 vaccine trials, but such
potentially protective effector responses have been difficult to evaluate, particularly in these …
potentially protective effector responses have been difficult to evaluate, particularly in these …
Differential neutralization of human immunodeficiency virus (HIV) replication in autologous CD4 T cells by HIV-specific cytotoxic T lymphocytes
H Chen, A Piechocka-Trocha, T Miura… - Journal of …, 2009 - Am Soc Microbiol
Defining the antiviral efficacy of CD8 T cells is important for immunogen design, and yet
most current assays do not measure the ability of responses to neutralize infectious virus …
most current assays do not measure the ability of responses to neutralize infectious virus …
[HTML][HTML] Anti-HIV potency of T-cell responses elicited by dendritic cell therapeutic vaccination
M Surenaud, M Montes, CS Lindestam Arlehamn… - PLoS …, 2019 - journals.plos.org
Identification and characterization of CD8+ and CD4+ T-cell epitopes elicited by HIV
therapeutic vaccination is key for elucidating the nature of protective cellular responses and …
therapeutic vaccination is key for elucidating the nature of protective cellular responses and …
Lentiviral vectors encoding human immunodeficiency virus type 1 (HIV-1)-specific T-cell receptor genes efficiently convert peripheral blood CD8 T lymphocytes into …
A Joseph, JH Zheng, A Follenzi, T DiLorenzo… - Journal of …, 2008 - Am Soc Microbiol
The human immunodeficiency virus type 1 (HIV-1)-specific CD8 cytotoxic T-lymphocyte
(CTL) response plays a critical role in controlling HIV-1 replication. Augmenting this …
(CTL) response plays a critical role in controlling HIV-1 replication. Augmenting this …
[HTML][HTML] Antigen-driven clonal selection shapes the persistence of HIV-1–infected CD4+ T cells in vivo
FR Simonetti, H Zhang, GP Soroosh… - The Journal of …, 2021 - Am Soc Clin Investig
Clonal expansion of infected CD4+ T cells is a major mechanism of HIV-1 persistence and a
barrier to achieving a cure. Potential causes are homeostatic proliferation, effects of HIV-1 …
barrier to achieving a cure. Potential causes are homeostatic proliferation, effects of HIV-1 …
How might we cure HIV?
DM Margolis - Current infectious disease reports, 2014 - Springer
Antiretroviral therapy (ART) does not eliminate HIV-1 from latently infected reservoirs, and
this remains the critical obstacle to the eradication of infection. Although ART is effective in …
this remains the critical obstacle to the eradication of infection. Although ART is effective in …
Prolonged antiretroviral therapy preserves HIV-1-specific CD8 T cells with stem cell-like properties
S Vigano, J Negron, Z Ouyang, ES Rosenberg… - Journal of …, 2015 - Am Soc Microbiol
ABSTRACT HIV-1-specific CD8 T cells can influence HIV-1 disease progression during
untreated HIV-1 infection, but the functional and phenotypic properties of HIV-1-specific CD8 …
untreated HIV-1 infection, but the functional and phenotypic properties of HIV-1-specific CD8 …
[HTML][HTML] DNA/MVA vaccination of HIV-1 infected participants with viral suppression on antiretroviral therapy, followed by treatment interruption: elicitation of immune …
M Thompson, SL Heath, B Sweeton, K Williams… - PloS one, 2016 - journals.plos.org
GV-TH-01, a Phase 1 open-label trial of a DNA prime—Modified Vaccinia Ankara (MVA)
boost vaccine (GOVX-B11), was undertaken in HIV infected participants on antiretroviral …
boost vaccine (GOVX-B11), was undertaken in HIV infected participants on antiretroviral …
A randomized controlled safety/efficacy trial of therapeutic vaccination in HIV-infected individuals who initiated antiretroviral therapy early in infection
MC Sneller, JS Justement, KR Gittens… - Science translational …, 2017 - science.org
Despite substantial clinical benefits, complete eradication of HIV has not been possible
using antiretroviral therapy (ART) alone. Strategies that can either eliminate persistent viral …
using antiretroviral therapy (ART) alone. Strategies that can either eliminate persistent viral …